33 results
424B5
ACXP
Acurx Pharmaceuticals Inc
15 Nov 23
Prospectus supplement for primary offering
4:49pm
;
we may avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our
8-K
EX-99.1
1ytjhkvir41s73bvs
3 Nov 23
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
4:05pm
424B3
10t8hyk0fhui3tkrelqg
13 Jul 23
Prospectus supplement
4:32pm
424B5
tgqoyc1
17 May 23
Prospectus supplement for primary offering
4:25pm
424B3
1v6bhjxa0j9 numnneg
23 Sep 22
Prospectus supplement
8:19am
424B5
bou5nmfv6c6f b0slgfg
25 Jul 22
Prospectus supplement for primary offering
4:26pm
S-3
730t0v6p7p2xtju76h
1 Jul 22
Shelf registration
8:46am
S-3
EX-4.5
9mz6cgzfnb6 d7ju239
1 Jul 22
Shelf registration
8:46am
S-3
EX-4.6
x9ph3hiatkmqd
1 Jul 22
Shelf registration
8:46am